Terms: = Breast cancer AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck AND Prognosis
8 results:
1. Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients.
Wang WQ; Zhang L; Yang F; Zhou HH; Zhang W; Zou Y; Liu R
Biomed Pharmacother; 2022 Nov; 155():113787. PubMed ID: 36271565
[TBL] [Abstract] [Full Text] [Related]
2. A Machine Learning Model to Predict the Triple Negative breast cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract] [Full Text] [Related]
3. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
[TBL] [Abstract] [Full Text] [Related]
4. Impact of an In Situ Component on Outcome After In-breast Tumor Recurrence in Patients Treated with breast-Conserving Therapy.
Laird J; Lok B; Siu C; Cahlon O; Khan AJ; McCormick B; Powell SN; Cody H; Wen HY; Ho A; Braunstein LZ
Ann Surg Oncol; 2018 Jan; 25(1):154-163. PubMed ID: 29094250
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.
Iglesia MD; Parker JS; Hoadley KA; Serody JS; Perou CM; Vincent BG
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27335052
[TBL] [Abstract] [Full Text] [Related]
6. Hypoxia regulation of phosphokinases and the prognostic value of pAKT in breast cancer.
Wennemers M; Stegeman H; Bussink J; Versleijen-Jonkers YM; van Laarhoven HW; Raleigh JA; Varia MA; Sweep FC; Span PN
Int J Biol Markers; 2013 Jun; 28(2):151-60. PubMed ID: 23558942
[TBL] [Abstract] [Full Text] [Related]
7. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
[TBL] [Abstract] [Full Text] [Related]
